Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
GeoVax Logo
GeoVax Growth Score
94
CB Rank
20266
Heat Score
79
GeoVax Labs develops vaccines that prevent and fight HIV infections that result in AIDS.
Founded
obfuscation
PublicPost-IPO Equity Smyrna, Georgia, United States11-50 geovax.com
Biotechnology
Health Care
Medical Device
Overview

GeoVax
Total Funding
obfuscation
Growth Score
94
Heat Score
79

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score94
4 pts
in past quarter
Heat Score 79
35 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About GeoVax

CB Rank
20266
GeoVax Labs develops vaccines that prevent and fight HIV infections that result in AIDS.
Founded
obfuscation
PublicPost-IPO Equity Smyrna, Georgia, United States11-50 geovax.com
Biotechnology
Health Care
Medical Device

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name GeoVax Labs Inc.
Operating Status Active
Stock Symbol  NASDAQ:GOVX
Company Type For Profit
Founders  Harriet L. Robinson
About the Company
GeoVax Labs operates as a biotechnology company focusing on developing vaccines that prevent and fight human immunodeficiency virus (HIV) infections that result in acquired immunodeficiency syndrome (AIDS). It was founded in 1988 and is based in Smyrna, Georgia, United States.
Phone Number 6783847281
Contact Email info@geovax.com
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
GeoVax is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Gedeptin®
A gene-directed enzyme prodrug therapy for treating solid tumors, focusing initially on advanced head and neck cancer.
GEO-CM04S1
A next-generation COVID-19 vaccine using a synthetic Modified Vaccinia Ankara vector expressing spike and nucleocapsid antigens, targeting immunocompromised and healthy adults.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 13
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 13
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GeoVax Logo
Post-IPO Equity - GeoVax
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
U.S. Department of Defense Logo
U.S. Department of Defense
—
Grant - GeoVax Logo
Grant - GeoVax
—
U.S. Department of Defense Logo
U.S. Department of Defense
—
Grant - GeoVax Logo
Grant - GeoVax
—
U.S. Department of Defense Logo
U.S. Department of Defense
—
Grant - GeoVax Logo
Grant - GeoVax
—
U.S. Department of Defense Logo
U.S. Department of Defense
—
Grant - GeoVax Logo
Grant - GeoVax
—
U.S. Department of Defense Logo
U.S. Department of Defense
—
Grant - GeoVax Logo
Grant - GeoVax
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 5 Board Members and Advisors 2 Contacts 23

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 28, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 24, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 20, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

11,534
97.47%
 in past month

IT Spend

$121.4KThis year, GeoVax is projected to spend $121.4K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Metaverse Logo
Metaverse
96
Counter-Drone Technology Logo
Counter-Drone Technology
95
Robot Assisted Surgery Logo
Robot Assisted Surgery
94

Actively Used Products

10GeoVax uses 10 technology products and services including HTML5, Office 365, and  Microsoft Outlook, according to G2 Stack.

Active Website Tech Count

3GeoVax is actively using 3 technologies for its website, according to BuiltWith. These include Common Crawl, Google Maps, and  CommonCrawl Top 5m.

Total IP

35The intellectual property of GeoVax includes 31 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, GeoVax has registered 4 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is GeoVax's headquarters? GeoVax is located in Smyrna, Georgia, United States.Who invested in GeoVax? GeoVax is funded by U.S. Department of Defense.When was the last funding round for GeoVax? GeoVax closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are GeoVax's competitors? Alternatives and possible competitors to GeoVax may include Eikon Therapeutics, NRx Pharmaceuticals, and  Allarity Therapeutics.How much funding has GeoVax raised to date? GeoVax has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(3237dbc 1)
|